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TOPICAL FORMULATIONS FOR THE
TRANSDERMAL DELIVERY OF NIACIN
AND METHODS OF TREATING
HYPERLIPIDEMIA

NeW combination niacin/statin formulation shoWs pro
nounced effects on major lipoproteins and Well tolerated, J

Am Coll Card Suppl. A 35: 326, 2000).
Niacin has been Widely used for reducing serum choles
terol levels because it is considered a cost-effective therapy.
In oral doses of 2 to 3 g daily, it reduces levels of total and
LDL-C by an average of 20% to 30%, reduces triglyceride
levels 35% to 55%, increases HDL-C 20% to 35%, and

This application claims the bene?t of Provisional Appli
cation Ser. No. 60/197,621 ?led Apr. 14, 2000.

reduces Lp(a) in humans. Niacin also reduces total mortality

FIELD OF THE INVENTION

This invention relates to topical formulations for trans

10

dermal delivery of niacin and esters and alcoholic fatty-acid
esters as described herein derivatives thereof and the trans

K., Stamler, J ., Friedman, L., Prineas, R. J. and FriedeWald,

dermal treatment of hyperlipidemia and hypercholester
olemia With these agents. Therapeutic uses of the system are
also described. The topical formulations are useful for, e.g.,

as Well as mortality from coronary artery disease (see The

Coronary Drug Project Research Group, JAMA 231:
360—381, 1975; and Canner, P. L., Berge, K. G., Wenger, N.

W., Fifteen year mortality in Coronary Drug Project patients:
15

long-term bene?t With niacin, J Am Coll Cardiol 8:
1245—1255, 1986.) and it helps to sloW or reverse the

treating hyperlipidemia in a mammal.
Hyperlipidemia and hypercholesterolemia are conditions

progression of atherosclerosis (see Blankenhorn, D. H.,
Nessim, S. A., Johnson, R. L., Samnarco, M. E., AZen, S. P.

that have a Well established correlation With increased risk
and other deleterious ailments. There are numerous agents

and Cashin-Hemphill, L., Bene?cial effects of combined
colestipol-niacin therapy on coronary atheroscloerosis and
coronary venous bypass grafts, JAIVIA 257: 3233—3240,

available for loWering cholesterol and lipid levels, including
gem?briZol, probucol, and, more recently, the “statins” e.g,

Samnarco, M. E., AZen, S. P. and Blankenhorn, D. H.,

of other conditions, such as heart attacks, atherosclerosis,

20

1987.; and Cashin-Hemphill L.; Mack, W. J., Pogoda, J. M.,

lovastatin.

Niacin (nicotinic acid), a Water soluble B-complex
vitamin, is used orally for the treatment of hyperlipidemia
and has been shoWn to be effective in reducing total plasma
cholesterol (C), loW density lipoproteins LDL-C and very

Bene?cial effects of colestipol-niacin on coronary athero
25

sclerosis. A 4-year folloW-up, JAMA 264: 3013—3017,

1990).
Oral niacin therapy has side effects that limit its utility.
Although niacin is a vitamin, it must be used in therapeutic
doses to loWer cholesterol. At these doses, both immediate

loW density lipoprotein triglycerides (VLDL-triglycerides),
are considered a “healthy” lipoprotein, in patients With type

release and sustained-release niacin can have several side
effects. The most common side effect of niacin is ?ushing,
a Warm feeling in the skin usually associated With redness

II, III, IV, and V hyperlipoproteinemia.
Although the mechanism by Which niacin alters lipid

and sometimes itching. Flushing is not dangerous but most
patients ?nd it very uncomfortable, Which seriously limits

all of Which are associated With health risks, While raising

30

serum levels of high density lipoproteins (HDL-C) Which

pro?les has not been Well de?ned, its mechanisms of action
have been shoWn to include inhibition of free fatty acid

35

can be substantially attenuated by pretreatment With

cyclooxygenase inhibitors, suggesting that the vasodilation
is caused by a prostaglandin-mediated mechanism (see

release from adipose tissue (see Carlson, L. A., Froberg, S.
O. and Nye, E. R., Nicotinic acid in the rat. 11. Acute effects

of nicotinic acid on plasma, liver, heart, and muscle lipids,
Acta Med Scand 180: 571—579, 1966), and increased lipo

Carlson, L. A., Nicotinic acid and inhibition of fat mobiliZ
40

protein lipase activity (see Priego, J. G., Pina, M., Armijo,
M., Sunkel, C. and Maroto, M. L., Action of eto?brate,
clo?brate and nicotinic acid on the metabolism of lipids in
normolipemic rats. Short term effects and method of action,

Arch Farmacol Toxicol 5: 29—42, 1979). More than 14

45

Liver function tests are alWays monitored in patients
taking niacin since elevation of serum transaminase levels
has been associated With niacin treatment, and sustained
release niacin formulations have been associated With more

and toxic effects of sustained- vs immediate-release niacin in
50

effective as a monotherapy but it also is bene?cial as a

combination therapy because it complements the effects of
other classes of lipid-loWering drugs. Niacin is a second or
third choice for isolated, hypercholesterolemia because of a
high incidence of side effects associated With oral niacin
therapy. HoWever, it has a therapeutic advantage as a mono
therapy When reduction of both LDL-C and triglycerides are
desired such as for patients With severe combined hyper
lipidemia. Niacin can also be used in combination With other
cholesterol-loWering agents such as the “statins” to maxi
miZe lipid-loWering activity. One study shoWs that a niacin/
lovastatin combination is highly effective in loWering LDL

55

C, triglycerides and lipoprotein a[Lp(a)] While retaining

65

niacin’s potency in raising HDL-C (Kashyap, M. L., Evans
R., Simmons, P. D., Kohler, R. M. and McGoven, M. E.,

ing lipolysis. Present status, of effects on lipid metabolism,
Adv Exp Med Biol 109: 225—23 8, 1978).

serious liver problems (see McKenney, J. M., Proctor, J. D.,
Harris, S., and Chinchili, V. M., Acomparison of the ef?cacy

million Americans have elevated blood LDL-C levels.
HMG-CoA reductase inhibitors (statins) are the most Widely

used class of drugs for treating patients With elevated levels
of LDL-C. Niacin, hoWever, is the only drug recommended
by the American Heart Association for HDL improvement in
primary prevention of cardiovascular diseases in addition to
loWering LDL-C. Niacin therapy is not only very cost

patient compliance With therapy. Niacin-induced ?ushing

60

hypercholesterolemic patients, JAMA 271: 672—777, 1994;
and Stafford, R. S., Blumenthal, D. and Pasternak, R. C.,
Variations in cholesterol management practices of US.
physicians, JAm Coll Cardiol 29: 139—146, 1997). Other
possible side effects of oral niacin therapy include activation
of peptic ulcers, gout, and Worsening of diabetes control.
Given the potential for side effects, oral niacin therapy
requires careful clinical monitoring.
The pharmacokinetic pro?le of niacin taken orally is
complex due to rapid and extensive ?rst-pass metabolism,
resulting in a nonlinear relationship betWeen niacin dose,
thus there is no correlation betWeen the lipid parameters and

plasma niacin levels. For example, data shoW that Niaspan®
doses of 1,000 mg results in an improvement in lipid pro?les
With barely detectable increases in plasma niacin (see Phy
sicians Desk Reference, 53rd edition, p 1505—1506, 1999).
Niaspan® is an extended release niacin formulation

approved by the FDA for the treatment of hypercholester

olemia and hypertriglyceridemia (CapuZZi, D. M., Guyton,

US 6,677,361 B2
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J. R., Morgan, J. M., Goldberg, A. C., Kriesberg, R. A.,

must be suf?ciently penetrated to provide the active agent to
the desired site for absorption into the bloodstream. Skin is
a complex organ system, consisting of multiple layers. The

Brusco, O. A. and Brody, J ., Ef?cacy and safety of an

extended-release niacin (Niaspan): A long term study, Am J
Cardiol 82: 74u—8 I u, 1998; and Morgan, J. M., CapuZZi, D.

uppermost, or “stratum corneum” layer of skin consists of

M., and Guyton, J. R., A neW extended-release niacin

non-living material derived primarily from the terminal
differentiation of epidermal keratinocytes, and provides a
protective barrier for the underlying components of skin.
The epidermis contains a number of cell types, although

(Niaspan): Efficacy, tolerability, and safety in hypercholes
terolemic patients,Am J Cardiol 82: 29u—34u, 1998). Thus,
signi?cant improvement in the serum lipid pro?le can be
achieved Without a dramatic increase in nicotinic acid

plasma levels after the oral administration of niacin (see

keratinocytes are the major cell type. Dermal ?broblasts are
10

Knopp, R. H., Alagona, P., Davidson, M., Goldberg, A. C.,
Kafonek, S. D., Kashyap, M., Sprecher, D., Superko, H. R.,
Jenkins, S., Marcovina, S., Equivalent ef?cacy of a time
release form of niacin (Niaspan) given once-a-night versus
plain niacin in the management of hyperlipidemia, Metabo
lism 47: 1097—104, 1998). This demonstrates that sustained

15

elevation of blood levels of niacin is not required to achieve

to penetrate the skin to the desired site or to blood vessels for

a therapeutic effect. Indeed, the data support the argument
that tissue saturation With niacin appears to be the key factor

systemic distribution.
The bene?ts of transdermal delivery indicate that trans
dermal delivery systems of niacin for, e.g, the treatment of

in obtaining therapeutic bene?t. Prolonged loW-level expo
sure via controlled release oral formulations is preferable to

hyperlipidemia or vitamin therapy are desirable.
It is an object of the present invention to provide trans

the high level, short exposures resulting from immediate
release formulations because it avoids inconvenient dosing

dermal delivery formulations and systems for the systemic

regimens and reduces unpleasant side effects. HoWever,
controlled release oral formulations of niacin still shoW

signi?cant degree of ?ushing and hepatic dysfunction. In

embedded Within a matrix comprised of collagen, elastin,
proteoglycans, and other extracellular matrix molecules.
Blood capillaries are found in the dermis, but the epidermis
is non-vascular.
Additionally, the drug itself must be suitable for admin
istration. The siZe of a drug molecule, its charge, and
polarity are factors that contribute to the ability of the agent

25

vieW of the pharmacokinetic fate of oral niacin, the ideal

delivery of niacin to a patient, e.g., a mammal such as a

human, Wherein the niacin is provided in a pro-drug of
niacin, e.g., nicotinic acid esters and fatty acid esters of the
corresponding alcohol. These are referred to herein as “pro
niacin”.
It is also an object of the invention to treat hyperlipidemia

method of niacin administration has yet to be achieved.
Transdermal drug delivery is an attractive route due to the

controlled input of these agents and avoidance of the hepatic

?rst-pass effect. HoWever, it is unlikely that hydrophilic

and hpercholesterolemia via transdermal delivery of niacin

compounds such as niacin Will easily permeate across the
skin. We demonstrate in the present study that the chemical
modi?cation With fatty alcohols alloWs niacin to permeate
the skin in a controlled manner for systemic delivery and to

using pro-niacin esters.

35

affect the blood lipid pro?le in animal models. Both chemi
cal and enZymatic hydrolysis of prodrug esters of niacin
have been extensively evaluated using human and rat plasma

These and other objects of the invention are achieved by
the present invention Which is described in the folloWing
disclosure.
BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 is depicts the NAD content in mouse skin treated

and hog liver carboxylesterase preparations described by
Wernly-Chung, G. N., Mayer, J. M., Tsantili-Koulidou, A.
and Testa, B., Structure-reactivity relationships in the chemi

With myristyl nicotinate for 7 days vs. untreated skin;
FIG. 2 is a table shoWing lipid response to Niaspan®;

cal hydrolysis of prodrug esters of nicotinic acid, Int J
Pharma 63: 129—134, 1990. The studies shoW that chemi

parameters for plasma niacin;

FIG. 3 is a table of the mean steady-state pharmacokinetic

cally stable niacin esters are excellent substrates of esterases.

A study indicates that the binding of niacin esters mainly

45

depends on lipophilicity (optimal log Pod/V523) and steric

untreated skin (4b);

factors. Niacin esters up to hexyl nicotinate are commer

FIG. 5 is a graph shoWing the cholesterol loWering effects

cially available.

of transdermal lauryl niacin ester vs. oral niacin in hairless

Transdermal delivery systems are a convenient and effec
tive alternative for the administration of many types of

medications, including anti-anginals (nitroglycerin), hor
mones (estrogens) and antihypertensives (cloncidine).
Transdermal delivery is bene?cial because the agents are

delivered directly into the blood stream, avoiding ?rst-pass
metabolism in the liver, so that drug delivery is continuous

FIGS. 4a and 4b are graphs comprising NAD content in
mouse skin treated With myristal niacin for 7 days (4a) vs.

55

and sustained. Transdermal delivery also provides a sus

tained and consistent delivery of medication, avoiding peaks
and valleys in blood levels Which are often associated With

oral dosage forms and Which are usually undesirable. Thus,

mice against a control; and
FIGS. 6a—a' is a graph shoWing the effect of oral niacin
and transdermal lauryl niacin on the lipid pro?les of apoB/
CETP transgenic mice.
FIG. 7 is a graph shoWing the effect of nicotinoyl laurate
compared to the results shoWn in FIG. 6.
FIG. 8 shoW the general chemical structures of nicotinate
and nicotinyl compounds suitable for use With the present
invention.
DETAILED DESCRIPTION OF PREFERRED
EMBODIMENTS

using transdermal delivery, one can administer loWer doses
of drug to achieve the same therapeutic effect compared to

oral administration, reducing or eliminating dose-dependent

Transdermal delivery is an attractive alternative route of

side effects.
Preparing suitable formulations of medications is a chal
lenging task, and many hurdles must be overcome to achieve

niacin administration that circumvents toxic ?rst-pass

hepatic actions. The topical delivery system of invention
65

takes into account the partitioning of niacin through the

a suitable topical dosage form. The skin, Which has protec

stratum corneum Which is at least partly controlled by the

tive layers designed to prevent penetration of foreign matter,

esteri?cation of niacin or addition of a fatty acid to form a

US 6,677,361 B2
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nicotinyl compound, collectively the pro-niacins of the

EXAMPLES 1 AND 2—PREPARATION OF
NIACIN ESTERS

present invention, such as those soWn in FIG. 7. The rate and

site of metabolic conversion of the pro-niacin contribute to

penetration of the skin and to systemic absorption into the
blood vessels in the loWer skin layers. The primary consid
eration for transdermal delivery of many hydrophilic drugs

Example 1
Nicotinic acid esters Were prepared by treating nicotinyl

such as niacin is the high diffusional resistance of the intact
stratum corneum. Molecular modi?cation of niacin the drug,
more commonly in the form of a prodrug, circumvents this

problem.
Niacin pro-drugs, e.g., nicotinic acid esters are preferred

over nicotinic acid because they provide prodrugs With
highly desirable formulation properties for transdermal
delivery. Additionally, conversion to niacin by esterases
present in skin provides sustained release of the active
ingredient. The C10—C18 esters of niacin are particularly

chloride With triethylamine (TEA), dimethylaminopyridine
(DMAP) and various C1 to C18 alcohols under nitrogen (all
10

chemicals obtained from Sigma Aldrich). The resultant
esters Were separated by silica gel column chromatography
and converted to their respective HCl salts for further

puri?cation. Thin layer chromatography (TLC) and IH-NMR
con?rmed the purity and identity of the ?nal products listed
15

preferred, although suitable formulations can be prepared
With C1 to C22 nicotinic acid esters. The niacin esters and

in Table 1 beloW. Examinations by TLC Were performed on

Analtech Uniplate silica gel GF plates. Column chromato
graphic puri?cations Were done With silica gel (Merck, 60 A,
230—400 mesh for ?ash chromatography).

nicotinyl compounds may be straight chain or branched,
substituted or unsubstituted provided the total number of
carbons meets the criteria set forth herein.

20

Example 2

25

These Were housed in solid bottom cages provided With
sterile feed and Water and lithium, With a 14:10 light-dark
cycle. The nicotinic acid esters of Example 1 Were applied
With a gloved ?nger daily to the backs of hairless mice in
200 mg of Vanicream LiteTM skin care lotion

It is preferred that the compositions comprise from 1 to

Female hairless mice (HRS-J. 6—8 Weeks old Were used.)

30% by Weight of the niacin prodrug, preferably 1—20%, and
most preferred 1—10%.
The niacin or niacin prodrug preferably has a log P of
from 0.5 to about 12, 4.5 to 10, most preferably from 4.8 to

9.7 When measured using Water/octanol partitioning.
To evaluate the ef?cacy of transdermal delivery, a hairless
mouse model and an apoB/CETP double transgenic mouse
model Was used. The apoB/CETP model provides a suitable
model of human lipid metabolism as these mice are knoWn

(Pharmaceutical Specialties, Inc., containing puri?ed Water,
White petrolatum, ceteareth alcohol and ceteareth-20, pro
30

monostearate, polyethylene glycol monostearate, sorbic acid

to display a lipoprotein cholesterol distribution most similar

to that of normolipidemic humans. Transgenic mice express
ing speci?c human genes have been Widely used to inves
tigate the lipid metabolism and to test potential hypolipi

35

demic drugs, providing the potential for better prediction of
the human response. Transgenic mice expressing both
human apoB100 and human CETP shoW a human-like
serum HDL-C/LDL-C distribution and are commercially

available. ApoB100 is a protein component of VLDL and
LDL, and it is the ligand responsible for binding to the LDL
receptor, Whereas CETP mediates the distribution of lipids
among different classes of lipoproteins. The lipoprotein

cholesterol pro?le of the double transgenic mice is signi?
cantly different from that of nontransgenic, human apoB

40

45

most of the cholesterol is found in the HDL fractions. The

apoB100/CETP double transgenic mice display the lipopro
tein cholesterol distribution most similar to that of normo
50

tein B and human CETP have a lipoprotein cholesterol

55

to treat those conditions.

SWenseid, M. E., Jacob, R. A. and McKee, R. W., Biochemi

levels of erythrocyte niacin coenZymes and plasma
tryptophan, J Nutrition 119: 1949—195 5, 1989). The sys
temic transdermal delivery of niacin Was assessed by deter
mining the NAD content of a skin site that is remotely

located from the site of topical application. Demonstration
of tissue saturation of niacin using a transdermal delivery
system according to the invention is shoWn in FIG. 1, Which
shoWs treatment With myristyl nicotinate.

NAD assay. The pellet Was dissolved in 1 ml of 0.1 M NaOH
for protein assay. NAD content Was assessed based on the

principle of enZymic cycling (Jacobson, E. L. and Jacobson,
M. K., Tissue NAD as biochemical measure of niacin status
60

in humans, Methods Enzymol 280: 221—230, 1997). The
BCA method (Pierce Chemical Co.) Was employed for
protein determination. Determination of Poet/W Was con

amount of a transdermal formulation containing a suf?cient,

i.e. therapeutically effective amount of niacin pro-drug in a
suitable topical base to the skin of a subject to reduce serum
cholesterol and/or lipid levels of LDL, VLDL’s, or to
increase serum HDL levels. Thus, the formulations may be
used to prevent hyperlipidemia and hypercholesterolemia, or

Since niacin is converted to NAD in tissue, NAD content
Was used as a marker of niacin saturation (Fu, C. S.,

For NAD and protein analyses, the tissue Was homog
eniZed using a Polytron in 1 ml of ice-cold 0.5 M HClO4 and
centrifuged at 3,000 rpm for 15 min. The supernatant Was
neutraliZed With ice-cold 2 M KOH/0.66 M KHZPO4 for the

described by Grass, D. S., Sainai, U., Felkner, R. H.,
Wallace, R. E., Lago, W. J. P., Young, S. G. and SWanson,
M. E., Transgenic mice expressing both human apolipopro
distribution similar to that of normolipidemic humans, J
Lipid Res 36: 1082—1091, 1995.
The topical formulations of the present invention can be
used to loWer cholesterol and/or lipids in a patient in need
thereof, mammals and humans, by applying a suf?cient

and BHT) at concentrations in the range of 0.5 to 2.0%
(Wt/Wt) for one Week. Control mice received 200 mg of the
lotion alone. The animals Were euthaniZed by cardiac injec
tion of pentobarbital prior to skin excisions. Dorsal and
ventral skin samples Were immediately froZen in liquid
nitrogen and stored at —80° C.

cal markers for assessment of niacin status in young men:

single transgenic and CETP single transgenic mice, in Which

lipidemic humans (i.e., a ratio of LDL-C to HDL-C of
approximately 2 to 1) When fed a normal choW diet

pylene glycol, sorbitol solution, simethicone, glyceryl

ducted using the reversed-phase HPLC method as reported

by Harnisch M., Mokel H., Relationship betWeen Log PoW
shake-?ask values and capacity factors derived from
65

revesed-phase high-performance liquid chromatography for
n-alkyl benZenes and some OECD reference substances. J.

Chrom, 282, (315—332), 1983. Results are shoWn in Table 1.

US 6,677,361 B2
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Example 5
Female apoB/CETP double transgenic mice (Taconic

TABLE 1

Biotechnology, Germantown, NY.) were divided into 6

Properties of Niacin Prodrugs

groups and housed in groups of 6 animals per. The lauryl

Erythematous

ester was used as a 5% lotion formulation and applied to the

Log P Value"

Response

0.84
1.3
2.4
3.5
4.8

Yes
Yes
Yes
Yes
Yes

shaved backs of the test animals receiving a standard diet, 5
times a week for 4 weeks. For oral administration, niacin
(sodium salt) was dissolved in drinking water at a concen
tration of 0.75% (0.63% as free acid). Niacin intake was
estimated from the water consumed. The estimated daily

10 carbons

5.8

Slight

12
13
14
15
16
18

6.6
7.5
7.6
8.3
9.2
9.7

No
No
No
No
No
No

Alkyl Carbon Chain Length
1
2
4
6
8

carbon
carbons
carbons
carbons
carbons
carbons
carbons
carbons
carbons
carbons
carbons

10

niacin intake was approximately 1,400 mg/kg.
The oral dose used was 760 mg/kg/day and the topical
dose was 250 mg/kg/day as niacin. The oral niacin dose
15

*Determined as described in Harnisch and Mokel, supra.

The results summarized in Table 1 supra show that
nicotinic acid esters with log P values between about 6.0 and
about 8.0 are the preferred compounds for transdermal
delivery of niacin to achieve tissue saturation, since esters

with log P values of less than about 6, including C1 to C8
esters, cause erythematous response, while esters with log P

20

25

values greater than 6 do not. The C10 ester showed reduced
erythematous response compared to C8 or lower esters.

30

1978. The treatment of niacin with various alkyl bromide
35

under nitrogen resulted in esters that could be separated by

silica gel column chromatography. The purity and identity of
the ?nal products were con?rmed by TLC, 1H-NMR

spectroscopy, reversed-phase HPLC, and elemental analy
sis. Niacin, DBU and all the alkyl bromides were purchased
from Sigma-Aldrich. Examinations by TLC were performed
on Analtech Uniplate silica gel GF plates. Column chro

40

37, 45% and 13%, respectively. These results show that
45

trometer using tetramethylsilane as the internal reference.

tion were conducted as described in Example 2, and the
results are shown in FIGS. 4a and 4b.

50

The results show niacin pro-drugs, e.g., niacin esters, can
be applied dermally as a prodrug to control blood lipid
imbalance as an alternative to oral niacin that circumvents

?ushing and potentially toxic ?rst-pass hepatic effects. The
55

results show that the topical treatment lowered total plasma
cholesterol level by 52%, whereas oral niacin lowered total

cholesterol by 12%.
The myristyl- and lauryl esters of niacin show no cuta
neous vasodilation, indicating that niacin prodrugs can be
made without such an undesirable effect. They provide
60

prodrugs with highly desirable formulation properties for
transdermal delivery and conversion to niacin by esterases
present in skin will provide a sustained release of the active

lected into microfuge tubes containing 10 pl of heparin,
plasma separated by centrifugation at 2,000><g for 15 min
utes and stored at —80° C. until analysis within 1 week. Total
cholesterol, HDL-C and triglycerides were measured

therapeutic for positively modulating serum lipid pro?les.
The results show that the topical treatment lowered total

Additionally, a plasma lipid analysis was performed by
taking fasting (16 h) blood samples of the hairless mice were
obtained at the beginning, at 30 days and 60 days from the
retroorbital plexus, and at the end of treatment by cardiac
puncture. The animals were euthanized by cardiac injection
of pentobarbital prior to blood collection. Blood was col

lauryl nicotinate can be highly effective as a transdermal

plasma cholesterol level by 52%, whereas oral niacin low
ered total cholesterol by 12%.

Example 4
Lauryl niacin esters prepared according to Example 3 was
evaluated in hairless mice using the procedure set forth in
Example 2 except that concentrations of 1 to 10% wt/wt.
lauryl niacin ester were used. NAD and protein determina

Improvement of lipid pro?les of apoB100/CETP trans
genic mice treated with niacin prodrug. The effect of trans
dermal delivery of lauryl niacin ester on plasma lipid
pro?les in a comparison with oral niacin in the apoB100/
CETP double transgenic mice for 90 days. A total of six
groups of six animals were used in this study. For topical
administration, lauryl niacin ester was applied daily to the
shaved backs of mice. For oral administration, niacin
(sodium salt) was dissolved in the drinking water. After 90
days, the topical treatment at one-fourth the dose of the oral
treatment lowered total cholesterol, triglycerides, and the
LDL-C fraction by 15, 33 and 38% while HDL-C was
elevated by 8%. The oral treatment lowered total

cholesterol, triglycerides, LDL, and HDL-C fractions by 29,

matographic puri?cations were done with silica gel (Merck,
60 A, 230—400 mesh for ?ash chromatography). 1H-NMR
spectra were recorded on a Varian Gemini-300 NMR spec

range of 34 to 340 mg/kg as niacin. Control mice received

equal amounts of the vehicle lotion alone. A lipid analysis

methods described by Ono, N., Yamada, T. Saito, T. Tanaka,
K. and Kaj i, A., A convenient procedure for esteri?cation of
carboxylic acids, Bull. Chem. Soc. Jpn. 51:2401—2404,

and 1,8-diazbicyclo[5,4,0]undec-7-ene (DBU) in benzene

1999. The oral dose, on the basis of body surface area, is
equivalent to a human dose of 3.7 g/day, while the topical
dose is equivalent to 1.2 g/day.
For topical administration, niacin lauryl esters was
applied daily to the shaved backs of mice in 200 mg of lotion
at concentrations of 1, 2, 5 and 10% (wt/wt) for 13 weeks.
Per 25-g mouse, the daily topical doses would be in the

was performed as described in Example 4. Results are
shown in FIGS. 6a—a'.

Example 3
Esters of niacin were also synthesized according to known

chosen is in the range of 500 to 900 mg/kg/day typically
used in preclinical rodent studies described by Santos, K. F.
R., Oliveira, T. T., Nagem, T. J., Pinto,A. S. and Oliveira, M.
G. A., Hypolipidaemic effects of naringenin, rutin, nicotinic
acid and their associations, Pharmacol Res 40, 493—496,

ingredient without vasodilation for optimum systemic deliv
65

ery. The results in animal models strongly suggest that the
transdermal approach can be successfully applied to the

enzymatically, using a clinical chemistry analyzer Syncrhon

overall improvement of lipid pro?les by niacin

CX7 by Beckman). Results are shown in FIGS. 4a and 4b.

administration, in humans or other mammals.
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Niacin and nicotinic acid esters and nicotinyl compounds
of the present invention penetrate and saturate tissue When

3. The method of claim 1, Wherein said compound is

administered to a subject, and as discussed above, tissue
saturation is related to reduction in serum cholesterol and

lipid levels shoWing transdermal delivery of niacin, particu
larly in ester form, Will effectively reduce serum LDL and
VLDL levels and/or increase serum HDL levels.
The nicotinic acid esters are suitable for transdermal

delivery, particularly C10 or greater esters, e.g., C10—C18
and most preferably C12—C16. HoWever, suitable formula

10

tions can be prepared With C8 or loWer esters, and they are

included Within the scope of the invention. Corresponding
nicotinyl compounds are also effective.

Wherein R, is C1—C22 alkyl.
4. The method of claim 1, Wherein said compound is

In addition to creams and lotions, topical formulations
such as shampoos, liquids such as eye Washes, balms and
sticks such as lip balms and deodorant sticks, soaps, patches,

bandages, suturing threads, coated implant devices, and any
other type of system designed for topical application. Suit
able pharmaceutical vehicles Will be used to prepare the

transdermal formulations of the invention, including

Wherein R is C1—C22 alkyl.
5. The method of claim 1, Wherein said compound is

petrolatum, Whitepsol ointment, various lotions, emulsion
bases, creams, and the like.
Most preferred is a transdermal delivery system. Suitable

myristyl nicotinate.
6. The method of claim 1, Wherein said compound is a
lauryl niacin ester.

transdermal delivery systems (patches) for delivery of nico
tine are knoWn in the art, such as those described in US. Pat.

7. A method for loWering serum LDL in a subject in need

No. 4,839,174; 4,943,435; and 5,016,652. Many other

thereof comprising topically administering to said subject an

eXamples of these types of devices are knoWn in the art.
Typical transdermal systems include a reservoir or matrix

amount of a compound of formula

containing the drug, and an adhesive layer Which is perme

O

able to the active agent, in this case niacin and more

O

preferably nicotinic acid esters. An adhesive layer, Which

/R

may be the same as the permeable layer, adheres to the skin

(l 3

of a subject, alloWing the agent to be released and absorbed
into the skin for subsequent systemic circulation and distri

\1

\1

N

N

e

O

2

(l 3
or

6

O

iR

2|

bution to other tissue. In operation, the device Will trans
dermally deliver a suf?cient dose of niacin or nicotinic acid
ester to deliver a suf?cient amount of niacin to saturate the

Wherein in each compound R is C1—C22 alkyl, in an

tissue of the subject With niacin, and to provide a reduction
in total cholesterol, VLDL, or LDL levels and/or an increase
or improvement in HDL levels. Improvements in total
cholesterol are conveniently expressed as a loWering of the

8. The method of claim 7, Wherein R is C10—C18 alkyl.
9. The method of claim 7, Wherein said compound is

amount suf?cient to reduce serum LDL in said subject.

ratio of total cholesterolzHDL or LDLzHDL. The result shoW

that transdermal delivery of the compounds described herein

produce improvements in the cholesterol and lipid pro?les
of the subjects similar to those knoWn to be produces With

oral niacin therapy.
Other features of the invention Will be clear to the skilled
artisan and need not be set forth herein.

Wherein R is C1—C22 alkyl.
10. The method of claim 7, Wherein said compound is

All references cited herein are incorporated by reference
in their entireties.
We claim:
1. A method of loWering serum triglyceride in a subject in

need thereof comprising topically administering to said
subject an amount of a compound of formula

55
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Wherein, in each compound R is C1—C22 alkyl, in an
amount suf?cient to reduce serum triglyceride in said 65

subject.
2. The method of claim 1, Wherein R is C10—C18 alkyl.

Wherein R is C1—C22 alkyl.
11. The method of claim 7, Wherein said compound is

myristyl nicotinate.
12. The method of claim 7, Wherein said compound is a
lauryl niacin ester.
13. A method of increasing serum HDL levels in a subject

in need thereof comprising topically administering to said
subject an amount of a compound of formula

US 6,677,361 B2
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wherein in each compound R is C1—C22 alkyl, in an

14. The method of claim 13, Wherein R is C10—C18 alkyl.
6 me

0/

R

(l 3
or

O

1R

6
2|
\1
N

wherein in each Compound R is C1—C22 alkyl, in an

amount sllf?cient I0 raise Serum HDL in said subject 10
15. Th

(l 3

6
2|
\1

O

amount suf?cient to

lower the ratio of total choles

tergli PLDL, aIId/OI (ii) lOWer the ratio of LDL;HDL in

th d f l '
13
h
'
'd
d '
O O C alm
, W erem Sal Compoun 1S

Sal S11 JeCL
18. The method of claim 17, Wherein R is C10—C18 alkyl.

15

19. The method of claim 17, Wherein said compound is

20

Wherein R is C1—C22 alkyl.
16. The method of claim 13, Wherein said compound is
O
25

|

O

wherein R is C1_C22 alkyL
20. The method of claim 17, Wherein said compound is

R

i

6\1 2

N

(l 3

30
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O

R
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\1
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Wherein R is C1—C22 alkyl.
17. A method of improving total cholesterol pro?le in a
subject in need thereof comprising topically administering to 35
said subject an amount of a compound of formula

wherein R is C1_C22 alkyL
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